Bifunctional CRBN Modulators for Selective Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as cancer lack effective targeting of aberrant proteins, particularly those mediated by cereblon, which are involved in the progression and proliferation of tumor cells, necessitating the development of compounds that can selectively degrade these proteins.
Innovation Solution
Bifunctional compounds are designed to bind to cereblon and recruit specific proteins for degradation, utilizing a targeting ligand that interacts with the E3 ubiquitin ligase complex to induce proteolysis of proteins like IKZF1 and BRD4, thereby modulating their activity and impacting disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancer, then general anti-cancer effects are achieved, but selective targeting of aberrant proteins mediated by cereblon is insufficient
Solution Approach 1:
The patent employs bifunctional compounds as intermediaries that bridge the cereblon protein and target proteins (such as IKZF1 and BRD4). These compounds contain a cereblon-binding moiety and a target protein-recruiting moiety, enabling selective recruitment of aberrant proteins to the CRL4^CRBN E3 ubiquitin ligase complex for degradation, thereby achieving reliable selective targeting while preventing tumor cell proliferation
2Reliability
If bifunctional compounds are designed to recruit specific proteins for degradation, then selective protein degradation is achieved, but device complexity increases
Solution Approach 1:
The bifunctional compounds are segmented into distinct functional modules: a cereblon-binding moiety (such as glutarimide or oxo-naphthoyl imide structures) and a target protein-recruiting moiety (such as bromodomain ligands). This segmentation allows each module to independently perform its function while simplifying the overall design process through modular assembly, reducing the effective complexity of developing selective protein degradation agents
3Reliability
If compounds bind to cereblon and induce proteolysis of target proteins, then therapeutic effects are achieved, but manufacturing precision requirements increase
Solution Approach 1:
The patent utilizes parameter changes in the chemical structures of bifunctional compounds, specifically varying the linker length and composition between the cereblon-binding and target protein-recruiting moieties. By optimizing parameters such as linker length (e.g., alkyl chains of different carbon numbers) and chemical properties, the compounds achieve effective target protein recruitment and degradation while maintaining feasible manufacturing precision through systematic structural modification rather than requiring extremely precise synthesis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate enhanced degradation of target proteins, leading to therapeutic effects in cancer treatment by modulating protein activity and reducing tumor cell proliferation.
Implementation Method 1
Cereblon has been identified as a common primary target for IMiDs... members of the Ikaros family of transcription factors, Ikaros and Aiolos (encoded by the genes Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 respectively) are recruited as protein substrates for CRL4^CRBN
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A
AI summary
Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.